What is the Indoco Remedies PE ratio today?
Indoco Remedies' PE ratio is 60.5 at the 29 October 2026 close (₹209.50 a share): a market capitalisation of ₹1,934 crore divided by consolidated net profit attributable to shareholders of ₹31.9 crore over the last four quarters (Q3 FY26 to Q2 FY27). These four quarters include net exceptional items of ₹132 crore (one-off gains reported separately), so the ratio on recurring profit would differ.
What is the Indoco Remedies PB ratio (price to book value)?
Indoco Remedies' price-to-book (PB) ratio is 1.89 at the 29 October 2026 close: a market capitalisation of ₹1,934 crore divided by shareholders' equity (book value) of ₹1,022 crore on 30 September 2026. That is a book value of ₹110.68 per share against a share price of ₹209.50.
What is the Indoco Remedies ROE and ROCE?
In FY26, Indoco Remedies' return on equity (ROE) was −9.7% and its return on capital employed (ROCE) was 1.0%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −6.9% and ROCE −0.9%.
What is the Indoco Remedies market cap?
Indoco Remedies' market capitalisation was ₹1,934 crore at the 29 October 2026 close: 9.23 crore shares at ₹209.50 each.
What is the Indoco Remedies EPS?
Indoco Remedies' basic earnings per share (EPS) were −₹10.70 in FY26. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹3.43.
What is the Indoco Remedies dividend in 2026 and its record date?
In 2026, Indoco Remedies has declared one dividend: ₹0.20 with record date 10 September 2026.
Is Indoco Remedies debt free?
No. Indoco Remedies had borrowings of ₹976 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.96. Its cash and current investments were ₹52.5 crore, so its net debt was ₹924 crore.
What is the Indoco Remedies debt to equity ratio?
Indoco Remedies' debt-to-equity ratio was 0.96 on 30 September 2026: borrowings of ₹976 crore against total equity of ₹1,016 crore. A year earlier, on 30 September 2025, it was 1.03.
What is the Indoco Remedies net worth?
Indoco Remedies' net worth — shareholders' equity in its consolidated balance sheet — was ₹1,022 crore on 30 September 2026, up 4.3% from ₹980 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,934 crore at the 29 October 2026 close.
What is the Indoco Remedies book value per share?
Indoco Remedies' book value per share was ₹110.68 on 30 September 2026: shareholders' equity of ₹1,022 crore divided by the 9.23 crore shares in issue, up 4.2% from ₹106.21 a year earlier. The share price at the 29 October 2026 close was ₹209.50.
What is the Indoco Remedies dividend yield?
Indoco Remedies' dividend yield is 0.10% at the 29 October 2026 close: dividends of ₹0.20 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹209.50. They were ₹0.20 on 10 September 2026.
What are the Indoco Remedies latest quarterly results?
Indoco Remedies' latest results are for Q2 FY27 (July–September 2026), filed on 27 October 2026: consolidated net profit attributable to shareholders ₹18.4 crore, against a loss of ₹7.9 crore in Q2 FY26; revenue from operations ₹520 crore, up 7.3% year on year.
What is the Indoco Remedies promoter holding?
Promoters held 58.92% of Indoco Remedies on 30 September 2026, up 0.06 percentage points from 58.86% the previous quarter and up 0.02 percentage points from 58.90% a year earlier, according to the shareholding pattern filed with NSE.
What is the Indoco Remedies free cash flow?
In FY26, Indoco Remedies generated ₹192 crore of cash from operations and spent ₹148 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹44.7 crore. In FY25 it was −₹261 crore.
What is the Indoco Remedies revenue and profit in FY26?
In FY26 (April 2025–March 2026), Indoco Remedies' consolidated net loss was ₹95.2 crore, wider than the loss of ₹73.7 crore in FY25, on revenue from operations of ₹1,845 crore (up 10.8%).
What is the Indoco Remedies shareholding pattern?
On 30 September 2026, Indoco Remedies' shares were held by promoters 58.92%, foreign portfolio investors (FII/FPI) 1.64%, domestic institutions (DII) 16.64% (including mutual funds at 16.44%) and retail and other non-institutional investors 22.66%. Over the year, FII holding was up 0.39 percentage points from 1.25% and DII holding was down 1.52 percentage points from 18.16%.
How does Indoco Remedies compare with its peers?
On FY26 consolidated figures, against Sai Parenterals, Panacea Biotec and Hikal: Indoco Remedies' operating margin of 0.8% is the third highest of the four (Sai Parenterals 5.7%, Panacea Biotec −5.9%, Hikal 3.3%; peer average 1.0%); its return on equity of −9.7% is the lowest of the four (Sai Parenterals 2.9%, Panacea Biotec −0.6%, Hikal −4.0%; peer average −0.6%).
Indoco Remedies vs Sai Parenterals: how do they compare?
In FY26, Indoco Remedies earned net profit attributable to shareholders of ₹95.2 crore on revenue of ₹1,845 crore, against ₹14.3 crore on ₹381 crore for Sai Parenterals. Indoco Remedies' operating margin was 0.8% (Sai Parenterals 5.7%) and its return on equity −9.7% (Sai Parenterals 2.9%). At the 29 October 2026 close, Indoco Remedies' market capitalisation was ₹1,934 crore against ₹2,234 crore for Sai Parenterals.
When are the Indoco Remedies next results?
Indoco Remedies has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
